Trodelvy will be used as a single agent to treat unresectable or metastatic HR-positive, HER2-negative breast cancer patients who have received endocrine-based therapy, and a minimum of two additional systemic therapies in the advanced setting.
View allCompanies IntelligenceGilead Sciences IncC H M P INCView all
The approval was granted after a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
It is based on data from the TROPiCS-02 study, which showed a statistically significant and clinically meaningful overall survival benefit of 3.2 months against comparator single-agent chemotherapy.
The international multicentre, open-label, Phase III study assessed Trodelvy against physicians’ choice of chemotherapy in 543 cases of HR+/HER2- metastatic breast cancerHR+/HER2- metastatic breast cancer previously treated with endocrine therapy, a CDK4/6 inhibitorCDK4/6 inhibitor and two to four lines of chemotherapy for metastatic disease.
Gilead Oncology therapeutic area head and senior vice-president Bill Grossman stated: “Trodelvy could change the outlook for women with pre-treated HR+/HER2- metastatic breast cancerHR+/HER2- metastatic breast cancer by replacing the standard-of-care chemotherapy that has been their only option for decades.
“We look forward to working with European authorities to ensure access for these patients who need new treatment options.”
Trodelvy has received approval in more than 40 countries and is currently undergoing regulatory reviews worldwide.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.